 
 
Official Title: A pi[INVESTIGATOR_2268], single -site study to assess the effect of exoskeletal support on 
motor control strategies in individuals with stroke  
NCT Number : [STUDY_ID_REMOVED]  
Study Number:  s23-[ZIP_CODE]  
Document Type:  Study Protocol and Statistical Analysis Plan 
Date of the 
Document:  ‚Ä¢ July 24, 2023 
 
 
Study #: s23-[ADDRESS_1153198] of exoskeletal 
support on motor control strategies in individuals with stroke  
 
Principal Investigator:  
 [INVESTIGATOR_830719], MD  
Department of Neurology  
[ADDRESS_1153199], 10th Floor 
[LOCATION_001], NY [ZIP_CODE] 
[PHONE_17311] [EMAIL_15790]  
[PHONE_17312]  
Additional  Investigator s: Alexander T. Brunfeldt, PhD  
Department of Neurology  
[ADDRESS_1153200], 10th Floor  
[LOCATION_001], NY [ZIP_CODE] [EMAIL_15791] 
[PHONE_17313]  
NYULMC Study Number:  s23-[ZIP_CODE]  
Funding Sponsor:  [CONTACT_830764]  
IDE Number:  N/A 
Regulatory Sponsor :  Heidi Schambra, MD  
 
Study Product:  Shoulder exoskeleton for gravity compensation (‚Äúexoskeleton‚Äù)  
Study Product Provider:  Custom device, built by [CONTACT_976]  
[CONTACT_103927].gov 
Number   N/A 
 
Initial version : 7 July 2023 
Amended: 24 July 2023  
Amended:  
Amended:  
Amended:  
 
Statement of Compliance 
This study will be conducted in accordance with the Code of Federal Regulations on the Protection of Human Subjects (45 CFR Part 46), 21 CFR Parts 50, 56, 312, and 812 as applicable, any other applicable US government 
research regulations, and institutional research policies and procedures. The International Conference on 
Harmonisation (‚ÄúICH‚Äù) Guideline for Good Clinical Practice (‚ÄúGCP‚Äù) (sometimes referred to as ‚ÄúICH -GCP‚Äù or ‚ÄúE6‚Äù) 
will be applied only to the extent that it is compatible with FDA and DHHS r egulations.  The Principal Investigator 
[INVESTIGATOR_7433], or changes to the protocol will take place without prior agreement from the sponsor and documented approval from the Institutional Review Board (IRB), except where necessary to elim inate 
an immediate hazard(s) to the trial participants. All personnel involved in the conduct of this study have completed 
Human Subjects Protection Training.  
  

Study #: s23-[ADDRESS_1153201] OF ABBREVIATIONS ...................................................................................................................................... 5 
PROTOCOL SUMMARY  ...........................................................................................................................................  6 
SCHEMATIC OF STUDY DESIGN  ...........................................................................................................................  7 
1 KEY ROLES  .....................................................................................................................................................  8 
2 INTRODUCTION, BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ...................................  8 
2.1 BACKGROUND INFORMATION AND RELEVANT LITERATURE  ...............................................................  8 
2.2 NAME [CONTACT_33914]  ..............................................................  8 
2.2.1  Preclinical Data  ....................................................................................................................................  9 
2.2.2  Clinical Data to Date  ............................................................................................................................ 9 
2.2.3  Dose Ra tionale (if applicable)  ..............................................................................................................  9 
2.3 RATIONALE  .................................................................................................................................... 9 
2.4 POTENTIAL RISKS & BENEFITS  .......................................................................................................  [ADDRESS_1153202] Storage and Stability  ............................................................................................................  16 
6.1.4  Preparation  ........................................................................................................................................ 16 
6.1.5  Dosing and Administration  ................................................................................................................. 16 
6.1.6  Route of Administration  ...................................................................................................................... 17 
Study #: s23-[ZIP_CODE]    Page 3 of 4 
 
6.1.7  Starting Dose and Dose Escalation Schedule  ................................................................................... 17 
6.1.8  Dose Adjustments/Modifications/Delays  ............................................................................................ 17 
6.1.9  Duration of Therapy  ...........................................................................................................................  17 
6.1.1 0 Tracking of Dose  ...........................................................................................................................  17 
6.1.11  Device Specific Considerations  .....................................................................................................  17 
6.2 STUDY AGENT ACCOUNTABILITY PROCEDURES  ............................................................................. 17 
7 STUDY PROCEDURES AND SCHEDULE  .................................................................................................... 17 
7.1 STUDY PROCEDURES /EVALUATIONS  .............................................................................................  17 
7.1.1  Study Specific Procedures  ................................................................................................................. 18 
7.1.2  Other Assays or Procedures  ..............................................................................................................  18 
7.2 STUDY SCHEDULE  .......................................................................................................................  18 
7.2.1  Screening ...........................................................................................................................................  18 
7.2.2  Enrollment/Baseline  ...........................................................................................................................  19 
8 ASSESSMENT OF SAFETY  .......................................................................................................................... 19 
8.1 SPECIFICATION OF SAFETY PARAMETERS  .....................................................................................  19 
8.1.1  Definition of Adverse Events (AE)  .....................................................................................................  19 
8.1.2  Definition of Serious Adverse Events (SAE) ...................................................................................... 19 
8.1.3  Definition of Unanticipated Problems (UP) ........................................................................................ 20 
8.2 CLASSIFICATION OF AN ADVERSE EVENT  ...................................................................................... 20 
8.2.1  Severity of Event  ................................................................................................................................  20 
8.2.2  Relationship to Study Agent  ..............................................................................................................  20 
8.2.3  Expectedness  ....................................................................................................................................  20 
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP ...................................  20 
8.4 REPORTING PROCEDURES ‚Äì NOTIFYING THE IRB ..........................................................................  21 
8.4.1  Adverse Event Reporting  ................................................................................................................... 21 
8.4.2  Serious Adverse Event Reporting  ...................................................................................................... 21 
8.4.3  Unanticipated Problem Reporting  ...................................................................................................... 22 
8.5 REPORTING PROCEDURES ‚Äì NOTIFYING THE STUDY SPONSOR  ......................................................  22 
8.6 REPORTING PROCEDURES ‚Äì NOTIFYING THE FDA ........................................................................ 23 
8.7 STUDY HALTING RULES ............................................................................................................... 23 
8.8 SAFETY OVERSIGHT  ....................................................................................................................  23 
9 CLINICAL MONITORING  ............................................................................................................................... 24 
10 STATISTICAL CONSID ERATIONS ............................................................................................................... 24 
10.1  STATISTICAL AND ANALYTICAL PLANS (SAP)................................................................................. 24 
10.2  STATISTICAL HYPOTHESES  ...........................................................................................................  24 
10.3  ANALYSIS DATASETS  ................................................................................................................... 24 
10.4  DESCRIPTION OF STATISTICAL METHODS  ...................................................................................... 25 
10.4.1  General Approach  .........................................................................................................................  25 
10.4.2  Analysis o f the Primary Efficacy Endpoint(s)  ................................................................................. 25 
10.4.3  Analysis of the Secondary Endpoint(s)  .........................................................................................  25 
10.4.4  Safety Analyses  .............................................................................................................................  25 
10.4.5  Adherence and Retention Analyses  ..............................................................................................  25 
10.4.6  Baseline Descriptive Statistics  .......................................................................................................  26 
10.4.7  Planned Interim Analysis  ............................................................................................................... 26 
10.5  SAMPLE SIZE ............................................................................................................................... 26 
10.6  MEASURES TO MINIMIZE BIAS.......................................................................................................  26 
10.6.1  Enrollment/Randomization/Masking Procedures  ..........................................................................  26 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  .............................................  26 
12 QUALITY ASSURANCE AND QUALITY CONTROL  ....................................................................................  27 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  .........................................................................................  27 
Study #: s23-[ADDRESS_1153203]  .................................................................................................... 27 
13.3  INFORMED CONSENT PROCESS  .................................................................................................... 27 
13.3.1  Consent/Assent and Other Informational Documents Provided to Participants  ............................ [ADDRESS_1153204] KEEPI[INVESTIGATOR_1645]  ............................................................................................... 29 
14.1  DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  .............................................................  29 
14.1.1  Data Collection Tools ‚Äì Mobile Health Technology .......................................................................  [ADDRESS_1153205] POLICY  ..............................................................................................................  31 
18 REFERENCES ............................................................................................................................................... 32 
19 ATTACHMENTS  ............................................................................................................................................. 34 
20 SCHEDULE OF EVENTS ............................................................................................................................... 34 
  
Study #: s23-[ADDRESS_1153206] of Abbreviations  
 
AE Adverse Event/Adverse Experience  
CIMT  Constraint -induced movement therapy  
VR Virtual reality  
OFCT Optimal feedback control theory  
EMG  Electromyography  
MRI Magnetic resonance imaging  
DWI Diffusion weighted image  
UE-FM Upper -extremity Fugl -Meyer Assessment  
CST Corticospi[INVESTIGATOR_830720] #: s23-[ADDRESS_1153207] of exoskeletal 
support on motor control strategies in individuals with stroke  
Short Title  Exoskeletal support in stroke  
Brief Summary  This interventional study will measure motor performance, including 3D 
movement analysis and muscle activity, in response to exoskeleton assistance. 
The cohort design will compare stroke patients to healthy controls. Data 
collection will be conducted in a single, 2- hour session. We will also access 
stroke patients‚Äô brain MRIs that were obtained as standard of care during acute 
admission for stroke.  
Phase  Pi[INVESTIGATOR_830721] a VR environment whether additional 
gravity compensation from exoskeletal support will improve bimanual 
coordination in stroke patients.  A second primary  objective is to determine 
intervention effects on muscle control processes underlying bimanual 
coordination.  As a secondary objective,  we aim to correlate these measures with 
measures of stroke lesion chara cteristics.  
Methodology  Cohort design  
Endpoint  The primary endpoints will be a 2% increase  in RC and a 5% decrease in MC. 
The secondary endpoint will be a significant relationship between the change in 
MC (% decrease in MC) and CSTLL with an R2 value gre ater than 0.4  
Study Duration  12 months  
Participant Duration  One, 2- hour session  
Duration of IP 
administration Approximate 15 minutes  
Population  24 participants; 12 with history of stroke more than 6 -months prior to enrollment, 
12 healthy age- and gender -matched controls. Males and females 18- years old 
and older from with and without diagnosis of stroke.  
Study Site  Single -center (NYULMC) 
Number of participants  24 
Description of Study 
Agent/Procedure  We use a custom designed and built exoskeleton device that applies a torque 
to both shoulders. Torque values do not exceed 50% of the torque due to gravity.  
The device is mounted to a testing chair and attached to the participant using 
Velcro straps.  
Reference Therapy  N/A 
Key Procedures  No clinical procedures are required  
Statistical Analysis  Inferential group statistics (t -test, mixed design ANOVA); correlation, linear 
regression  
 
  
Study #: s23-[ZIP_CODE]    Page 7 of 8 
 
Schematic of Study Design 
 
 
Prior to  
Enrollment  
  
  
Visit 1  
Time Point  
 
  
 
  
  Total 24: Obtain informed consent. Screen potential participants  by [CONTACT_117473]; obtain history, document.  
Protocol testing  
(Collect 3 -dimensional motion capture, electromyography data; ask for HIPPA 
release to obtain neuroimaging data from medical record)  
Final Assessments  
Arm trajectory analysis  
(relative contribution)  
Electromyographical analysis 
(muscle contribution)  
Neuroimaging analysis  
(lesion load)  
Study #: s23-[ADDRESS_1153208], 10th Floor  
[LOCATION_001], NY [ZIP_CODE]  
T 929- 455-5128 (ACC)  
[EMAIL_15790]  
 Study Investigator  
Alexander T. Brunfeldt, PhD, Postdoc  
[ADDRESS_1153209], 10th Floor  
[LOCATION_001], NY [ZIP_CODE]  
Phone:  [PHONE_17313]  
[EMAIL_15791]  
2 Introduction , Background Information and Scientific Rationale  
2.1 Background Information and Relevant Literature  
Stroke is the 5th leading cause of death in the [LOCATION_002], and nearly 8 million Americans report it as their primary 
cause of disability (Virani et al., 2021). Of particular concern is that 38% of stroke survivors report major difficulty in using their impaired arm (Duncan et al., 2003). Recent advances in rehabilitation sciences have identified learned 
non use as a potential mechanism by [CONTACT_830737] (Taub et 
al., 2006). Therapy programs such as constraint -induced movement therapy (CIMT) have been developed to 
counter learned non use; however, these therapi[INVESTIGATOR_830722], 
expense, and the lack of bimanual training tasks (Kwakkel et al., 2015; Wolf et al., 2006). Therefore, there exists a 
critical need for new stroke therapi[INVESTIGATOR_830723].  
 
Our innovative approach uses virtual reality (VR), in conjunction with custom -built exoskeletons, to provide stroke 
patients with the task and environmental factors needed to increase use of their paretic limb. Therefore, the long-
term goal of this work is to develop device-based rehabilitative platforms that promote impaired arm use in chronic stroke. VR based applications have emerged as new treatment approaches in stroke rehabilitation settings over the 
last ten years. One of the most important advantages that a VR system can provide is that it allows researcher to create visual  environment s which surround the user to in a way that cannot be possible in physical reality. For 
example, by [CONTACT_830738] a virtual object, it is possible to couple the hands to promote increased use of the paretic limb during reaching (Diedrichsen, 2007) .  
 
We also use a custom -built exoskeleton to provide assistance to the impaired arm in stroke patients. Specifically, 
the exoskeleton provides gravity compensation, a process where the force of gravity is canceled out, fully or partially, by [CONTACT_830739] m echanics (Chen et al., 2019). Exoskeletons have been used for research purposes 
for decades, and emerging clinical applications are at the forefront of motor impairment rehabilitation sciences 
(Collins et al., 2015; Gueye et al., 2021; Keeling et al., 2021) . 
 Our current understanding of the combination of VR and exoskeleton modalities to i mprove arm function in stroke 
is lacking.  The specific aim of this study is to determine if gravity compensation, via exoskeleton loading, can 
increase impaired arm use in stroke participants during a VR reaching task.  This study will advance the field of 
stroke rehabilitation by [CONTACT_830740]- control reaching tasks in VR as a potential therapeutic 
solution for upper extremity stroke impairment.  
 Recently, we completed a feasibility study in which we show our protocol is safe and effective in altering limb coordination in 12 healthy control subjects (Brunfeldt et al., 2022). Moreover, we completed a study in 14 chronic 
stroke survivors and found they tolerated the procedures without incident (Brunfeldt et al., 2023, in review ). Our 
study in stroke survivors additionally shows that integrity of the corticospi[INVESTIGATOR_830724]. This paves the way for mechanistic approaches to neuroimaging biomarker  studies 
(Cassidy et al., 2018; Stinear, 2017; Zhu et al., 2010) . 
2.[ADDRESS_1153210] an IND or IDE  status.  
 
Study #: s23-[ZIP_CODE]    Page 9 of 10 
 
The device is a wearable, non-implantable exoskeleton designed to provide gravity compensation. Gravity 
compensation is defined as the application of torque to the shoulder that counteracts the torque due to gravity. That 
is, the torque vs. angle  profile is equal and opposite to that of gravity. For the purposes of this study, we will only 
use a 50% gravity compensation (i.e., the magnitude of torque is 50% that of gravity). The purpose of the device is 
to assist stroke participants while they reach for virtual objects in a VR environment . 
2.2.1 Preclinical Data 
The study investigator, Alexander Brunfeldt, PhD,  recently completed a study  at the  MedStar Health Research 
Institute (STUDY00004671) using these devices on 14 stroke participants. We did not find a significant change in 
RC or MC (primary endpoints) at the group level. However, we did find individual differences in outcomes that could 
be explained by [CONTACT_830741].  Specifically, stroke participants with more overlap between the lesion and 
the corticospi[INVESTIGATOR_830725] a smaller change in muscle activity during exoskeletal support compared to no exoskeletal support (Brunfeldt et al., in review ). We did not observe any adverse event.   
2.2.2 Clinical Data to Date 
N/A. No c linical data to date.   
2.2.3 Dose Rationale  
The 50% gravity compensation level was selected based on previous research in healthy controls (Brunfeldt et al., 2022)  and our recently completed study (Brunfeldt et al., in review ). In both studies, 50% was sufficient to change 
arm coordination and was well tolerated by [CONTACT_4317].  
2.3  Rationale 
This study is aimed at evaluating whether additional gravity compensation using an exoskeleton device will improve 
bimanual coordination chronic stroke survivors. The study addresses key limitations such as allowing participants 
to use both arms to perform activities of daily living, opposed to the traditional impaired -only approach in CIMT. Our 
study also allows for the identification of neuromuscular mechanisms of arm control in stroke. Specifically, we 
hypothesize that exoskeleton loading will increase reaching distance of the impaired arm while simultaneously 
decreasing the amount of muscle activity required. Our initial studies show individual differences in each participant‚Äôs responsiveness to our device. Therefore, we hypothesize that there is a relationship between motor 
performance and lesion characteristics such as size and location of the stroke infarct. Our cohort design allows us 
to compare motor performance between stroke survivors and age -matched healthy controls. This allows us to test 
specific predictions from the optimal feedback control theory (OFCT) approach to movement (Todorov & Jordan, 
2002) . Specifically, we can identify each participant‚Äôs sensitivity to different forms of sensory feedback (e.g., vision  
vs. proprioception). This information is critical in developi[INVESTIGATOR_830726]- based rehabilitation protocols. 
There are no specific problems associated with using healthy controls as a control group. We will take every precaution to ensure demographic balancing between groups.  
2.4 Potential  Risks & Benefits 
2.4.1 Known Potential Risks 
 
Potential risks of the exoskeleton include arm fatigue and soft -tissue (e.g., muscle, skin) discomfort. Fatigue is not 
greater than minimal risk because the arm movements will mimic reaching for an object on a shelf at eye level. No 
more than 54 reaches will be made in any single testing block, and these reaches are self -paced. Soft -tissue 
discomfort may arise from the exoskeleton applying a force to the arm. Discomfort poses no greater than minimal risk because the participant will only wear the device for approximately 5 minutes during the data collection phase. Also, the magnitude of force applied to the arm is no more than 50% of that due to gravity. The upper arm weighs 
approximately 5.77% of body weight ((Plagenhoef et al., 1983). For example, a 150 lbs. person would receiving a loading amount to counter 8.65 lbs. of force. The exoskeleton device will be worn during all testing blocks, however, the load is only applied during the ‚Äòloading phase‚Äô which lasts approximately 5 minutes.  
 
Study #: s23-[ADDRESS_1153211], and they may take a break and/or discontinue 
the study at any time.  
 
To limit the risks associated with VR headset and exoskeleton use, we will provide the participant with breaks every 
5-minutes. Also, all reaches will be self- paced. Participants will be verbally instructed that they may request 
unscheduled breaks during the data collection blocks. These unscheduled breaks will not affe ct data integrity. We 
also use padding and elastic gauze on the arms to reduce pressure and abrasion risk.  
 
There is a potential risk of breach of confidentiality. To mitigate this, procedures will be carried out in a laboratory 
space on the NYULMC campus. We are requesting personal health information from the patient‚Äôs medical record. 
To mitigate this, access will only be granted to named persons on this protocol; data wi ll be stored on TrialMaster.  
 
 
2.4.[ADDRESS_1153212] benefit to individual study participants.  
 Information gained in this study will inform the next generation of rehabilitative therapi[INVESTIGATOR_830727]. 
The potential benefits to the stroke community outweigh the potential risks to participants due to participants‚Äô 
exposure to no more than minimal risk.  
 
This study aims to explore the optimal control strategies implemented during reaching. As learned nonuse 
represents a maladaptive compensation in response to upper extremity dysfunction, targeted rehabilitative therapi[INVESTIGATOR_830728]. While this study cannot address the probability, magnitude, or duration of potential benefits, we 
expect a future iteration of these procedures could help the nearly 8 million stroke survivors living with disability.  
3 Objectives and Purpose  
3.1 Primary Objective 
To identify the effects of gravity compensation from exoskeletal support on bimanual coordination in stroke participants  during a reaching task in VR. Specifically, we will determine if gravity compensation can increase the 
reaching displacement of the impaired arm relative to the non- impaired arm. We will compare stroke participant 
perfor mance to healthy controls to determine if stroke influences an individual‚Äôs kinematic responsiveness to 
exoskeletal  support.  
 To determine the effects of gravity compensation from exoskeletal support on bilateral muscle activity in stroke participants. Specifically, we will determine if gravity compensation can reduce the required muscle activity needed 
to perform the VR reaching task. We will compare stroke and healthy control participant muscle activity to determine 
if stroke influences an individual‚Äôs neuromuscular responsiveness to exoskeletal support.  
3.[ADDRESS_1153213] lesion load as a correlate of kinematic and neuromuscular responsiveness to exoskeletal support. We do this by [CONTACT_830742] (or MC) with the variance in overlap between the 
lesion and the corticospi[INVESTIGATOR_88735] (CST lesion load) using clinical standard of care MRI scans.  
Study #: s23-[ADDRESS_1153214] will be asked to sit on a chair, wear the Oculus 
headset, and hold a touch controller in each hand to reach through a target 
displayed in the VR system (Figure 1). Subjects can see two avatar‚Äôs hands, representing their own hands  movements, in the VR environment. Each 
experimental block includes [ADDRESS_1153215] is asked to put his/her hands on his/her laps as a starting position. After the start position is achieved, a target cube will show up in the VR environment and the subject 
will use both hands to reach the cube. A cursor, located at the midpoint of 
the hands, will be used to ‚Äòhit‚Äô the target cube during each trial. The same horizontal locations of the targets used in a previous VR study will be used 
(Wang et al., 2021). Target locations will span the workspace from 
approximately ¬±15 degrees located at shoulder and eye level. This distribution is chosen to simulate reaches typi[INVESTIGATOR_830729]. The sequence of target locations will be randomized. Subjects‚Äô hand 
moveme nts will be confined to a quadrant and the radius will be scaled to 
each subject‚Äôs arm length, within the subject‚Äôs comfortable range of motion. 
Subjects can move at their own comfortable speed.  
 
Exoskeleton device  
Subjects will be asked to wear an exoskeleton device (Figure 2). This exoskeleton was designed and constructed 
by [CONTACT_830743]. Gravity assistance will be applied to the impaired 
arm of stroke patients and to the non -dominant arm of healthy controls. Gravity resistance will be applied to the 
non-impaired arm of stroke patients and to the dominant arm of healthy controls. Assistance/resistance levels are 
adjusted to provide a 50% change in arm weight based on the shoulder torque required to abduct the upper extremity. For example, for a 150lb person, the 50% resistance configuration would simulate adding a weight, W, 
equal to 2.[ADDRESS_1153216] (0.5*T = 0.5*BW*0.0533*0.447 = W*0.7687) (Plagenhoef et al., 1983). More detail on 
the exoskeleton device is in Section 6 Study Agent.  
 
Electromyography  
Figure 1: Oculus Rift headset and 
touch controller bundle  
 
Study #: s23-[ZIP_CODE]    Page 12 of 13 
 
Muscle activity will be measured using 
surface electromyography (EMG). Non-
invasive electrodes (Biometrics Ltd, [LOCATION_006]) will be applied to the skin of the subject 
over several muscles of interest including 
anterior deltoid (bilaterally), triceps (bilaterally) and the short head of th e 
biceps brachii (bilaterally). Maximum voluntary contraction will be assessed [ADDRESS_1153217] will 
be provided between MVC assessments. 
These data will be used to normalize 
outcome measures. EMG muscle activity will be recorded throughout each session.  
 
Neuroimaging 
Finally, we will obtain neuroimaging data from the participant‚Äôs electronic medical record (EMR). The Study 
Investigator will obtain written consent (see Consent Form) to access the participant‚Äôs EMR, where they will 
download the diffusion weighted image (DWI) scan obtained through standard of care at NYULMC. No ne w 
imaging will be required. Downloaded DWI images will have personal identifying information removed. The DWI 
will be analyzed in the ITK -SNAP ( http://www.itksnap.org/pmwiki/pmwiki.php ). We use this software to manually 
trace the lesion to obtain a lesion mask. This lesion mask is then standardized to the Montreal Neurological Institute 
stereotaxic space (Mazziotta et al., 2001)  using the SPM12 mappi[INVESTIGATOR_55072] (Karl Friston, 
https://www.fil.ion.ucl.ac.uk/spm/ ). We then determine the overlap between the lesion mask and the CST (Zhu et 
al., 2010) . 
 
Study T imeline  
The study will take place on the NYULMC campus in a single, 2-hour session.  
4.2 Study Endpoints 
4.2.1 Primary Study Endpoints 
The primary endpoints will be a 2% increase in RC and a 5% decrease in MC. These values are taken from 
(Brunfeldt et al., 2022). 
4.2.2 Secondary Study Endpoints 
The secondary endpoint will be a significant relationship between the change in MC (% decrease in MC) and CSTLL with an R
2 value greater than 0.4 (Brunfeldt et al., in review ). 
4.2.3 Exploratory Endpoints 
N/A 
5 Recruitment  
Starting immediately after IRB approval and lasting for approximately 12 months, subjects will be acquired by [CONTACT_537136]. The Study Investigator (Alexander Bru nfeldt, PhD) will recruit subjects via a participant 
registry maintained by [CONTACT_079] (Heidi Schambra, MD). The participant registry includes both 
survivors of stroke and healthy control participants.  The registry is maintained by [CONTACT_978] [CONTACT_1639] ‚Äúdevelop a resource that 
researchers can use to recruit healthy individuals and patients with stroke in IRB -approved studies conducted by 
[CONTACT_830744]‚Äù ( s18-[ZIP_CODE] ).  We may also recruit participants through word of mouth from other studies 
cond ucted in the PI‚Äôs laboratory.  
Figure 2: Exoskeleton in gravity resistance configuration  
 
Study #: s23-[ZIP_CODE]    Page 13 of 14 
 
 
The patient‚Äôs affected hand will be examined to determine if the patient‚Äôs impairment satisfies inclusion/exclusion 
criteria in one of the NYULMC treatment rooms allocated for research activities.  After it is determined that the 
subject is eligible to participate in the study, the consent process will proceed.  During the consenting process, all 
subjects will have the purpose of the experiment, the complete procedure, and any potential risks involved in participation in the study explained to them by [CONTACT_473]. Participants in the stroke group will receive a one -
time $50 check following their participation in our study. Healthy control participants will receive a one- time $25 
check. The reason for this difference in value is the potential for increased burden on stroke patients regarding transportation (i.e., some are not medically cleared to operate a motor vehicle) and care due to their impairment.   
5.[ADDRESS_1153218] meet all of the following criteria:  
 
Healthy controls  
1. Having obtained the age of 18 years  
2. Neurologically healthy (i.e., no history of: traumatic brain injury, peripheral neuropathy, seizures, etc.)  
3. Strongly right -handed according to at least 80% score on the Edinburgh Handedness Inventory (Oldfield, 
1971; Veale, 2013). The use of right -handed participants is a common feature in this field of study. This is 
due to the slight differences in arm control between left - and right -handed individuals (Sainburg & Kalakanis, 
2000) . 
4. Ability to give informed consent  
 
Survivors of stroke  
1. Having obtained the age of [ADDRESS_1153219] a diagnosis of stroke more than six months prior to entry into the study;  
3. have the ability to reach, unsupported, to approximately 70% of arm length  
4. ability to give informed consent  
 
5.2 Exclusion Criteria  
An individual who meets any of the following criteria will be excluded from participation in this study:  
 
All participants  
1. have any conditions that limit their capability of using a Head Mounted Display (HMD) for a VR environment 
or cooperate with the protocol.  
2. have any orthopedic injuries to the upper extremities.  
3. Have neurological injuries other than stroke.  
4. Have excessive pain in any joint of either arm that could limit the ability to cooperate with the protocols.  
5. Visuospatial neglect  
6. Apraxia 
7. Global inattention  
8. Legal blindness  
5.[ADDRESS_1153220] 0% of the contact[CONTACT_830745]. These patients will have already consented in the past; therefore, a formal capacity assessment is not warranted.  Informal judgment that prospective participants have the capacity to 
consent will be made through routine interactions with the individual during the consent process. Capacity wil l be 
determined by [CONTACT_830746]‚Äôs verbal understanding of the protocol including the purpose, objectives, potential risks and benefits of participation.  We will explicitly ask them to reco llect 
Study #: s23-[ZIP_CODE]    Page 14 of 15 
 
the purpose, risks, and benefits after explaining and prior their signing the consent form.  We will not consent or 
enroll any individual suspected of diminished capacity to consent.  
5.3.2 Assessment of Capacity 
Assessment of capacity will be done by [CONTACT_2035], Al exander Brunfeldt, PhD.  The assessors are study 
team members that are identified in Research Navigator.  
 
The individual performing the assessment and/or monitoring ongoing capacity will perform the assessment through 
routine interaction with the prospective participant during the consent process.  
 
The results of the capacity assessment will not be placed in the subject‚Äôs medical record. Results will not be placed 
in the participant‚Äôs medical record because we are not performing a formal capacity assessment.  
 
Prospective subjects will be informed of the results of the capacity assessment after it‚Äôs conducted. If an individual 
is found not to have the capacity to consent, the assessor will explain this to the individual. The assessor will provide 
the necessary resources and referrals for further care and evaluation.  
5.3.3 Surrogate Consent  
N/A. Enrolled participants will possess capacity and therefore not require a surrogate.  
5.3.[ADDRESS_1153221]‚Äôs capacity, 
a capacity assessment will be conducted as described above. Subjects who lose capacity will be withdrawn from 
the study. Subjects who appear to be unduly distressed will be withdrawn from the study.  
5.[ADDRESS_1153222]. An investigator may terminate participation in the study if:  
‚Ä¢ Any clinical adverse event (AE) or other medical condition or situation occurs such that continued 
participation in the study would not be in the best interest of the participant  
‚Ä¢ The participant meets an exclusion criterion (either newly developed or not previously recogniz ed) that 
precludes further study participation  
‚Ä¢ The participant fails to adhere to protocol requirements 
‚Ä¢ Subject withdraws consent  
‚Ä¢ Subject experiences excessive fatigue or discomfort  
 
Abrupt withdrawal or termination from study will not affect participant safety or clinical management.  
Study #: s23-[ADDRESS_1153223] recruitment and retention policies outlined in 5.4 Strategies for Recruitment and Retention.  
5.7 Premature Termination or Suspension of Study 
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. Written 
notification, documenting the reason for study suspension or termination, will be provided by [CONTACT_830747]. If the study is prematurely terminated or suspended, the PI [INVESTIGATOR_830730](s) for the termination or suspension.  
Circumstances that may warrant termination or suspension include, but are not limited to:  
‚Ä¢ Determination of unexpected, significant, or unacceptable risk to participants  
‚Ä¢ Insufficient compliance to protocol requirements  
‚Ä¢ Data that are not sufficiently complete and/or evaluable 
‚Ä¢ Determination of futility  
 Study may resume once concerns about safety, protocol compliance, data quality are addressed and satisfy the 
sponsor and/or IRB.  
6 Study Device  
6.1 Study Device 
We designed a bilateral exoskeleton to apply a torque to the shoulder joint when participants reach for targets in a  
virtual reality environment. We use r ubber bands to apply force to the upper arm about an axis of rotation pointing 
through the glenohumeral joint. The mechanics are designed to ensure the torque profile generated by [CONTACT_830748] a range of motion from neutral 
(anatomical position) to [ADDRESS_1153224] two operating modes. In the gravity 
assistance mode, the torque vector points opposite (180 degrees) that of the gravity torque vector. In the gravity 
resistance mode, the torque vector points in the same direction (0 degrees) as the gravity torque vector. That is, 
torque profiles are equal to 50% in magnitude, but opposite in direction to that of gravity. We apply  gravity assistance 
to the impaired arm  (non-dominant for healthy controls) and gravity resistance to the non -impaired arm of our stroke 
participants.  
 
This study will use two devices: an Oculus Rift Headset and a custom -built exoskeleton.  
Oculus Rift headset :  The Oculus Rift is a commercially -available virtual reality headset manufactured and sold by 
[CONTACT_830749]. It is used to present the visual environment in which participants perform the reaching task.  
This is not a medical device in the context of the study since we are not evaluating the safety or efficacy of this 
dev
ice in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease.  
 In addition the device is not intended to affect the structure or any function of the body.  
 
Exoskeleton Device: T
 he exoskeleton device was designed and constructed by [CONTACT_1704], Alexander 
Brunfeldt, PhD. The bilateral device is used to support the impaired arm (non- dominant in healthy controls) against 
gravity while simultaneously resisting movement of the non-impaired arm of stroke participants.  We consider the 
device to be a non -significant risk device as it meets the criteria for an abbreviated IDE. Please see the ‚ÄúAppendix: 
Investigational Device‚Äù in the Devices section for justif ication.  
6.1.1 Acquisition 
The exoskeleton device was designed and constructed by [CONTACT_1704], Alexander Brunfeldt, PhD. This 
device is stored in a locked room on the NYULMC campus. The device will only be used by [CONTACT_830750].  
Study #: s23-[ZIP_CODE]    Page 16 of 17 
 
6.1.2 Formulation, Appearance, Packaging, and Labeling 
We designed the exoskeleton in SolidWorks (Dassault Systems, Aachen, [LOCATION_013]). A schematic of the shoulder 
pi[INVESTIGATOR_830731] 3. Planar pi[INVESTIGATOR_6928] (e.g., arm pi[INVESTIGATOR_13959]) were laser cut from 1/4‚Äù  acrylic. Volumetric pi[INVESTIGATOR_6928] (e.g., 
arm holster) were 3D printed using ABS plastic.  
 
The exoskeleton device is mounted to the participant testing chair using a custom -built frame . The frame was 
constructed from 1‚Äù T -slotted framing rails, which allowed us to raise and lower the exoskeleton device so that its 
axis of rotation aligned with the glenohumeral joint. We placed the participant‚Äôs arm into the holster pi[INVESTIGATOR_13959] (Figure 
3, left panel) and secured it using two Velcro straps. Rubber bands were looped around two needle- roller bearings 
to reduce friction. These rubber bands produced a force directed along a vector pointing from the distal needle 
bearing towards the proximal one, indicated by [CONTACT_830751] 3, right panel. In the configuration 
shown in Figure 3, the rubber bands produced a torque directed against gravity (assist mode). We could move the 
proximal needle bearing to the inferior portion of the device to produce a torque in the same direction as gravity (resist mode).  The device is investigational and not commercially marketed.  
6.1.[ADDRESS_1153225] Storage and Stability 
The device will be stored at the offices of the study team in a locked testing room. The device does no expi[INVESTIGATOR_1312].  
6.1.4 Preparation  
N/A. The agent is not an IDS.  
6.1.5 Dosing and Administration 
Based on the mechanics of the device, derived in our previous study (Brunfel dt et al., in review ), we determined the 
number of rubber bands needed to produce 50% gravity compensation:  
 
The final calculations yielded the following linear relationships  
ùúèùúèùëéùëéùëéùëéùëéùëéùëéùëéùëéùëéùëéùëé = 1. 089ùëÅùëÅ5"ùë•ùë•5/8"+ 0. 16ùëÅùëÅ7"ùë•ùë•1/8"‚àí0.13 (ùëÅùëÅùëÅùëÅ) 
and 
ùúèùúèùëüùëüùëüùëüùëéùëé ùëéùëéùëéùëéùëéùëé = 0. 722ùëÅùëÅ7"ùë•ùë•5/8"+ 0. 17ùëÅùëÅ7"ùë•ùë•1/8"+ 0.7 (ùëÅùëÅùëÅùëÅ) 
 
Figure 3: Left shoulder exoskeleton device in assist mode. Left panel:  Isometric view of the exoskeleton. Right panel:  
Sagittal view of the exoskeleton with arm holster removed.  
Study #: s23-[ZIP_CODE]    Page 17 of 18 
 
where N is the number of rubber bands with subscript indicating length and width (i.e., ùëÅùëÅ5"ùë•ùë•5/8" is the number of 
5‚Äùx5/8‚Äù rubber bands). For example, the rubber band configuration for an individual with arm length of ~0.57m and 
weight ~75kg:  
 Assist mode:  5x5‚Äùx5/8‚Äù + 2x7‚Äùx1/8‚Äù = 5.64 Nm, which is approximately 50.7% of the torque due to gravity of her 
fully outstretched arm.  
Resist mode:  6x7‚Äùx5/8‚Äù + 3x7‚Äùx1/8‚Äù = 5.54 Nm, which is approximately 49.8% of the torque due to gravity of her 
fully outstretched arm . 
 
6.1.6 Route of Administration 
The study device will be attached to the participant using Velcro straps. The device be supported by a metal frame attached to a chair in which the participant is seated.  The device setup will be performed by [CONTACT_830752], 
Alexander Brunfeldt, PhD.  
6.1.7 Starting Dose and Dose Escalation Schedule 
Starting dose is 50% gravity compensation. There is no escalation.  
6.1.8 Dose Adjustments/Modifications/Delays 
There will be no dose adjustment or modification. 
6.1.9 Duration of Therapy  
Study participants will complete all requirements within the single, 2-hour session. They will wear the device for no 
more than 15 minutes.  
6.1.10 Tracking of Dose 
Torque levels will be set by [CONTACT_830753] a per -participant basis, equal to 50% of the torque due to 
gravity.  
6.1.11 Device Specific Considerations 
‚Ä¢ Device size. Approximately 1 meter, fully extended  
‚Ä¢ Device model. N/A. Custom, non- commercial device.  
‚Ä¢ Device settings and programming. 50% gravity compensation.  
‚Ä¢ Duration of implant or exposure. No more than 15 minutes.  
‚Ä¢ Frequency of exposure. One.  
6.2 Study Agent Accountability Procedures  
N/A. The study agent is not a pharmaceutical or investigational drug agent.  
7 Study Procedures  and Schedule  
7.1 Study Procedures/Evaluations 
Both stroke participants and healthy c ontrols will participate in a single session. Both groups will undergo the same 
protocol with two exceptions. Stroke participants will be asked to provide permission to review their medical records; they will also perform the Fugl -Meyer Assessment if no recent score has been obtained.  
Task  Stroke  Controls  
Consent  X X 
Inclusion/exclusion  X X 
Demographic Information  X X 
Edinburg h Handedness Inventory ‚Äì Short From  X X 
Study #: s23-[ZIP_CODE]    Page 18 of 19 
 
Fugl-Meyer Assessment (as needed)  X  
Virtual Reality Task (with EMG and exoskeleton)  X X 
Access & download neuroimaging  X  
7.1.1 Study Specific Procedures 
‚Ä¢ Medical history:  stroke information (date, location, hemorrhagic vs. ischemic)  
‚Ä¢ Medication history:  None 
‚Ä¢ Radiographic or other imaging assessments.  No new assessments will be acquired, but we will obtain 
standard of care imaging from hospi[INVESTIGATOR_063].  
‚Ä¢ Biological specimen collection and laboratory evaluations.  None  
‚Ä¢ A discussion of if the results of any study specific procedures (e.g., radiographic or other imaging or 
laboratory evaluations) will be provided to participant.  None.  
‚Ä¢ Counseling procedures . None  
‚Ä¢ Assessment of study agent adherence. N/A. No investigational agent  
‚Ä¢ Administration of questionnaires or other instruments for patient -reported outcomes, such as a daily diary.  
If participants do not have an Edinbu rgh Handedness Survey, one will be given to them. See Appendix.  
 
7.1.2 Other Assays or Procedures 
Fugl-Meyer Assessment and Edinburg h Handedness Inventory Questionnaire data will be used to screen for 
eligibility. The MOBILIS ([CONTACT_830765]‚Äôs) laboratory registry contains these data  (s17-[ZIP_CODE], s18 -[ZIP_CODE]) . 
7.[ADDRESS_1153226] of care.  
 Participants will be contact[CONTACT_830754], during which the Study Investigator will provide the prospective participant with a synopsis of the purpose and objectives of the research, a brief description of the 
protocol, and any potential risks and benefits. The prospective participant will be verbally informed that participation 
is completely voluntary. Upon verbal agreement of the prospective participant, the Study Investigator will schedule 
the single visit at the participant‚Äôs earliest convenience, usually within one -week of initial contact.  
 The Study Investigator will also ask verbal consent to view the prospective participant‚Äôs medical records. We inform the participant that no data will be downloaded or collected about the medical record, only that we use this to screen 
those with acute MRI imaging and to obtain the Fugl -Meyer  assessment score (see Section 6.1).  
 
The single session will begin with the informed consent process. After obtaining consent, we will gather information 
about the participant (e.g., age, height, weight, etc.; see Section 10 ). We then administer the Edinburg h 
Handedness Inventory Short Form (Oldfield, 1971; Veale, 2013). We then let the participant practice with the VR 
headset; we attach the EMG  sensors; we attach the exoskeletons. We then start data collection on the VR task 
protocol. Participants finish their participation with maximum voluntary contraction measurement. We then provide the participant with the appropriate stipend amount and ask  them if they have any questions/concerns about their 
participation.  
7.2.1 Screening  
Screening Visit (Day -28 to -1)  
‚Ä¢ Contact [CONTACT_830755], text, SendSafe, or MyChart. Provide verbal information about 
purpose, objectives, procedures, any potential risks and benefits to participation  
‚Ä¢ Ask permission to access medical records. Study Investigator will screen for those participants with acute DWI neuroimaging in the NYULMC system. No data will be collected or downloaded at this point in the study. This is only for screening purposes.  
Study #: s23-[ZIP_CODE]    Page 19 of 20 
 
‚Ä¢ We will also determine if the participant has a recent Fugl -Meyer assessment (within 12 months). If no 
Fugl-Meyer score is available, the Study Investigator will administer the assessment during the visit 
(~15 minutes).  
‚Ä¢ Instruct participants that they are to wear or bring a short -sleeved shirt to the visit. This is so we can attach 
the EMG leads to the participant‚Äôs arms.  
7.2.2 Enrollment/Baseline 
As this is a single- session observational study, enrollment, baseline, and testing is planned in the same visit. 
 
Enrollment/Baseline Visit (Visit 1, Day 0)  
‚Ä¢ Obtain and document consent from participant on study consent form.  
‚Ä¢ Verify inclusion/exclusion criteria.  
‚Ä¢ Obtain demographic information.  
‚Ä¢ Edinburgh handedness survey  
‚Ä¢ Administer full protocol.  
8 Assessment of Safety  
8.1 Specification of Safety Parameters  
No study endpoint are considered safety parameters. No safety parameters will be recorded. The dose of 50% gravity compensation has been used in our previous work with no reports of adverse events (Brunfeldt et al., 2022, 
Brunfeldt et al., in review ). 
8.1.1 Definition of Adverse Events (AE)  
An adverse event  (AE) is any symptom, sign, illness or experience that develops or worsens in severity during the 
course of the study.  Intercurrent illnesses or injuries should be regarded as adverse events.  Abnormal results of 
diagnostic procedures are considered to be adverse events if the abnormality:  
‚Ä¢ results in study withdrawal  
‚Ä¢ is associated with a serious adverse event  
‚Ä¢ is associated with clinical signs or symptoms  
‚Ä¢ leads to additional treatment or to further diagnostic tests  
‚Ä¢ is considered by [CONTACT_1372]  
8.1.2 Definition of Serious Adverse Events (SAE)  
Serious Adverse Event  
Adverse events are classified as serious or non -serious.  A serious adverse event is any AE that is:  
‚Ä¢ fatal 
‚Ä¢ life-threatening 
‚Ä¢ requires or prolongs hospi[INVESTIGATOR_4408]  
‚Ä¢ results in persistent or significant disability or incapacity  
‚Ä¢ a congenital anomaly or birth defect  
‚Ä¢ an important medical event  
 Important medical events are those that may not be immediately life threatening, but are clearly of major clinical 
significance. They may jeopardize the subject, and may require intervention to prevent one of the other serious 
outcomes noted above. For example, drug overdose or abuse, a seizure that did not result in in -patient 
hospi[INVESTIGATOR_059], or intensive treatment of bronchospasm in an emergency department would typi[INVESTIGATOR_60062].  
 
All adverse events that do not meet any of the criteria for serious should be regarded as non -serious adverse 
events.  
Study #: s23-[ZIP_CODE]    Page 20 of 21 
 
8.1.3 Definition of Unanticipated Problems (UP)  
Unanticipated Problems Involving Risk to Subjects or Others  
Any incident, experience, or outcome that meets a ll of the following criteria:  
‚Ä¢ Unexpected in nature, severity, or frequency (i.e. not described in study -related documents such as the IRB -
approved protocol or consent form, the investigators brochu re, etc)  
‚Ä¢ Related or possibly related to participation in the research  ( i.e. possibly related means there is a reasonable 
possibility that the incident experience, or outcome may have been caused by [CONTACT_226592])  
‚Ä¢ Suggests that the  r esearch places subjects or others at greater risk of harm  (including physical, 
psychological, economic, or social harm).  
This definition could include an unanticipated adverse device effect, any serious adverse effect on health or safety 
o
r any life -threatening problem or death caused by, or associated with, a device, if that effect, problem, or death 
was not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device 
that relates to the rights, safety, or welfare of subjects (21 CFR 812.3(s)).  
8.2 Classification of an Adverse Event  
8.2.1 Severity of Event  
For AEs not included in the protocol defined grading system, the following guidelines will be used to describe severity.  
‚Ä¢ Mild ‚Äì Events require minimal or no treatment and do not interfere with the participant‚Äôs daily activities.  
‚Ä¢ Moderate  ‚Äì Events result in a low level of inconvenience or concern with the therapeutic measures. 
Moderate events may cause some interference with functioning.  
‚Ä¢ Severe ‚Äì Events interrupt a participant‚Äôs usual daily activity and may require systemic drug therapy or other 
treatment. Severe events are usually potentially life-threatening or incapacitating.  
8.2.2 Relationship to Study Agent  
The clinician‚Äôs assessment of an A E's relationship to study agent (drug, biologic, device) is part of the 
documentation process, but it is not a factor in determining what is or is not reported in the study. If there is any 
doubt as to whether a clinical observation is an AE, the event should be reported. All AEs must have their relationship to study agent assessed. In a clinical trial, the study product must always be suspect. To help assess, 
the following guidelines are used.  
 
‚Ä¢ Related ‚Äì The AE is known to occur with the study agent, there is a reasonable possibility that the study 
agent caused the AE, or there is a temporal relationship between the study agent and event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study agent and the 
AE. 
‚Ä¢ Not Related  ‚Äì There is not a reasonable possibility that the administration of the study agent caused the 
event, there is no temporal relationship between the study agent and event onset, or an alternate etiology has been e stablished.  
8.2.3 Expectedness 
Alexander Brunfeldt, PhD  will be responsible for determining whether an AE is expected or unexpected. An AE will 
be considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk information previously described for the study agent.  
8.3 Time Period and Frequency for Event Assessment and Follow -Up 
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and interviews of a study participant presenting for medical care, or upon review by a study monitor. All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the appropriate RF. Information to be 
collected includes event description, time of onset, clinician‚Äôs assessment of severity, relationship to study product 
Study #: s23-[ZIP_CODE]    Page 21 of 22 
 
(assessed only by [CONTACT_8703] a diagnosis), and time of resolution/stabilization of 
the event. All AEs occurring while on study must be documented appropriately regardless of relationship. All AEs 
will be followed to adequate resolution.  
 
Any medical condition that is present at the time that the participant is screened will be considered as baseline and 
not reported as an AE. However, if the study participant‚Äôs condition deteriorates at any time during the study, it will be recorded as an AE. UPs will be recorded in the data collection system throughout the study.  
 Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity to be performed. AEs characterized as intermittent require documentation of onset and duration of 
each epi[INVESTIGATOR_1865].  
 The PI [INVESTIGATOR_15356] 
7 (for non-serious AEs) or 30 days (for SAEs) after the last day of study participation. At each study visit, the 
investigator will inquire about the occurrence of AE/SAEs since the last visit. Events will be followed for outcome 
information until resolution or s tabilization.   
 
All unresolved adverse events should be followed by [CONTACT_1374], the subject is 
lost to follow -up, or the adverse event is otherwise explained.  At the last scheduled visit, the investigator should 
instruct  each subject to report any subsequent event(s) that the subject, or the subject‚Äôs personal physician, believes 
might reasonably be related to participation in this study.  The investigator should notify the study sponsor of any 
death or adverse event occurring at any time after a subject has discontinued or terminated study participation that 
may reasonably be related to this study.  The sponsor should also be notified if the investigator should become 
aware of the development of cancer or of a congenital anomaly in a subsequently conceived offspring of a subject 
that has participated in this study.  
8.4 Reporting Procedures ‚Äì Notifying the IRB  
8.4.[ADDRESS_1153227] seek information on adverse events by [CONTACT_5147], as appropriate, by [CONTACT_5148].  Information on all adverse events should be recorded immediately in the 
source document, and also in the appropriate adverse event module of the case report form (CRF).  All clearly 
related signs, symptoms, and abnormal diagnostic procedures results should be recorded in the source document, 
though should be grouped under one diagnosis.  
 
All adverse events occurring during the study period must be recorded.  The clinical course of each event should be 
followed until resolution, stabilization, or until it has been determined that the study treatment or participation is not 
the cause.  Serious adverse events that are still ongoing at the end of the study period must be followed up to 
determine the final out come.  Any serious adverse event that occurs after the study period and is considered to be 
possibly related to study participation should be recorded and reported immediately.  
8.4.[ADDRESS_1153228] be reported are those that are:  
‚Ä¢ related to study participation,  
‚Ä¢ unexpected, and  
‚Ä¢ serious or involve risks to subjects or others.  
 For Narrative Reports of Safety Events 
If the report is supplied as a narrative, the minimum necessary information to be provided at the time of the initial report includes:  
Study #: s23-[ZIP_CODE]    Page 22 of 23 
 
‚Ä¢ Study identifier  
‚Ä¢ Study Center  
‚Ä¢ Subject number  
‚Ä¢ A description of the event  
‚Ä¢ Date of onset  ‚Ä¢ Current status  
‚Ä¢ Whether study treatment was discontinued  
‚Ä¢ The reason why the event is classified as serious  
‚Ä¢ Investigator assessment of the association 
between the event and study treatment  
 
8.4.3 Unanticipated Problem Reporting  
In the event of a UP, the study investigators will send a UP report to the IRB.  The UP report will include the following 
information:  
‚Ä¢ Protocol identifying information: protocol title and number, PI‚Äôs name, and the IRB project number;  
‚Ä¢ A detailed description of the event, incident, experience, or outcome;  
‚Ä¢ An explanation of the basis for determining that the event, incident, experience, or outcome represents an 
UP; 
‚Ä¢ A description of any changes to the protocol or other corrective actions that have been taken or are proposed 
in response to the UP.  
 
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:  
‚Ä¢ UPs that are SAEs will be reported to the IRB within one week  of the investigator becoming aware of the 
event.  
‚Ä¢ Any other UP will be reported to the IRB  within one week  of the investigator becoming aware of the problem.  
‚Ä¢ All UPs should be reported to appropriate institutional officials (as required by [CONTACT_17347]‚Äôs written 
reporting procedures), the supporting agency head (or designee), and OHRP within one week  of the IR‚Äôs 
receipt of the report of the problem from the investigator.  
8.5 Reporting Procedures ‚Äì Notifying the Study Sponsor  
The study investigat ors will complete a SAE Form within the following timelines:  
 
‚Ä¢ All deaths and immediately life- threatening events, whether related or unrelated, will be recorded on the 
SAE Form and submitted to the study sponsor within [ADDRESS_1153229] information.  
‚Ä¢ Other SAEs regardless of relationship will be submitted to the study sponsor within [ADDRESS_1153230] the understanding of the event.  Significant new information on ongoing unanticipated 
adverse effects shall be provided promptly to the study sponsor.  
Study #: s23-[ADDRESS_1153231] as FDA requests.  
8.6 Reporting Procedures ‚Äì Notifying the FDA  
 
The following describes the IDE safety reporting requirements by [CONTACT_830756]:  
‚Ä¢ Within 5 working days (via written report)  
‚Äì Protocol deviation to protect the life of the subject in emergency  
‚Äì Withdrawal of IRB approval  
‚Äì Lack  of informed consent  
‚Ä¢ Within 10 working days (via telephone or facsimile report)  
Any study event that is:  
‚Äì associated with the use of the study device, and  
‚Äì unanticipated, regardless of the seriousness of the event.  
 
Additional reporting requirements  
Sponsors are also required to identify in safety reports all previous reports concerning similar adverse events and to analyze the significance of the current event in light of the previous reports.  
 
Reporting Process  
Adverse events will be  in a narrat ive format. As such, t he minimum information to be supplied is noted above at 
the beginning of section this section . The contact [CONTACT_118690] : 
 
Reports will be sent via the FDA.gov website using the FDA Form 3500  
 
 
8.7 Study Halting Rules 
No halting rules will be used. The study poses no more than minimal risk to participants. Participants are free to withdraw at any time for any reason.  
8.8 Safety Oversight  
It is the responsibility of the Principal Investigator [INVESTIGATOR_16462]/her site.  This safety 
monitoring will include careful assessment and appropriate reporting of adverse events as noted above, as well as the construction and implementation of a site data and safety -monitoring plan (DSMP) . Medical monitoring will 
include a regular assessment of the number and type of serious adverse events.  
 
Data Safety Monitoring Plan  
Safety oversight will be under the direction of the study PI, Heidi Schambra, MD and the study investigator, 
Alexander Brunfeldt, PhD . The DSMP members  will meet twice, once at the 6- month time point and again at the 12 
month time point,  to assess safety data on each arm of the study.  Safety will be assessed by [CONTACT_830757], 
percentage, magnitude, and fr equency of:  
‚Ä¢ Headache  
‚Ä¢ Dizziness 
‚Ä¢ Arm soft- tissue discomfort  
‚Ä¢ Complaints  (non- specific to anticipated risks)  
‚Ä¢ Breaches of confidentiality  
Study #: s23-[ADDRESS_1153232] of the trial is in compliance with 
the currently approved protocol/amendment(s), with GCP, and with applicable regulatory requirement(s) : 
‚Ä¢ The NYU Human Research Protection Program may monitor the progress of the study. Monitoring will occur  
at the HRP‚Äôs discretion on a random basis at any frequency it deems necessary to ensure compliance and study safety.  
‚Ä¢ Independent audits will not be conducted to ensure monitoring practices are performed consistently across 
all participating sites.  This is  a single -site study.  
‚Ä¢ Each clinical site will perform internal quality management of study conduct, data collection, documentation 
and completion. An individualized quality management plan will be developed to describe a site‚Äôs quality 
management.  
10 Statisti cal Considerations  
10.1 Statistical and Analytical Plans (SAP)  
There will not be a formal SAP . 
10.[ADDRESS_1153233] comparing MC from 
baseline to loading blocks.  
 Secondary endpoint . There will be an association between change in RC (or MC) and CST lesion load. Independ ent 
linear regressions (RC vs. CSTLL and MC vs. CSTLL).  
 Secondary endpoint . RC values in stroke participants will be less than RC values in healthy controls during baseline 
blocks (t- test). MC values in stroke participants will be greater than MC values in healthy controls during baseline 
blocks (t- test). 
10.3 Analysis Datasets 
All participants  will be included the analysis dataset. The analysis dataset will include all relevant variables:  
Outcome variables  
‚Ä¢ Relative contribution (RC)  
‚Ä¢ Muscle contribution (MC)  
‚Ä¢ CST lesion load (CSTLL)  
 Independent variables  
‚Ä¢ Loading (via exoskeleton)  
 
Demographic variables  
‚Ä¢ Age 
‚Ä¢ Height  
‚Ä¢ Weight  
‚Ä¢ Time since stroke (stroke only)  
‚Ä¢ Lesion type (hemorrhagic vs. ischemic)  ‚Ä¢ Arm length  
‚Ä¢ Handedness  
‚Ä¢ Fugl-Meyer score (stroke only)  
 
Study #: s23-[ZIP_CODE]    Page 25 of 26 
 
10.4 Description of Statistical Methods  
10.4.1 General Approach 
This study is a repeated measures cohort design. Two groups of participants (stroke, healthy control) will perform 
a reaching task with and without an exoskeleton device. Primary endpoint measures will be compared within- subject 
to assess the effects of exoskeleton loading on coordination (kinematic: RC and muscular: MC). A between -subjects 
analysis will be performed to assess differences in arm control between stroke and healthy control participants.  
‚Ä¢ For descriptive statistics, we will use ranges, means, and standard deviation as appropriate. For  example 
individual ages will be reported and further summarized with mean and standard deviation.  
‚Ä¢ For inferential statistics, we will perform two -tailed paired- and unpaired t -tests and ANOVA where 
appropriate. Statistical significance will be assessed at  the Type -I error less than p = 0.05 level. See Section 
10.4.2.  
‚Ä¢ Covariates will not be pre -specified  
‚Ä¢ Statistical test assumptions will be analyzed following data collection. Appropriate adjustments (e.g., 
normality) will be performed, such as transformation or the use of non- parametric tests.  
10.4.2 Analysis of the Primary Efficacy Endpoint(s) 
Primary study objective (change in RC, MC)  
‚Ä¢ Two- way ANOVAs on RC are conducted with within- subjects factor block (baseline, loading, retention) and 
between- subjects factor co hort (healthy, stroke). Three -way ANOVAs on MC are performed with within-
subjects factors block and muscle (deltoid, biceps) and between- subjects factor cohort.  
10.4.3  Analysis of the Secondary Endpoint(s)  
Secondary study objective (Motor performance vs. CST lesion load)  
‚Ä¢ We first perform linear regressions to assess the relationship between lesion load and Upper Extremity Fugl-Meyer (UE -FM). Coefficient of determination (R2) values ranging from 0.[ADDRESS_1153234] been previously 
reported (Cassidy et al. , 2018; Feng et al., 2015; Lin et al., 2019; Zhu et al., 2010) .  
‚Ä¢ We regress lesion load into the change in RC (ŒîRC), change in MC (ŒîMC), and tradeoff slope. Any motor 
performance measures that fail to achieve R
[ADDRESS_1153235] lesion load 
will be discarded from further analysis.  
10.4.4 Safety Analyses 
The study does not contain safety endpoints. Adverse events will be coded using the following identifying  table:  
 
If the report is supplied as a narrative, the minimum necessary information to be provided at the time of the initial 
report includes:  
‚Ä¢ Study i dentifier  
‚Ä¢ Study Center  
‚Ä¢ Subject number  
‚Ä¢ A description of the event  
‚Ä¢ Date of onset  ‚Ä¢ Current status  
‚Ä¢ Whether study treatment was discontinued  
‚Ä¢ The reason why the event is classified as serious  
‚Ä¢ Investigator assessment of the association 
between the event and study treatment  
 
10.4.[ADDRESS_1153236]. Brunfeldt is under full control of the administration of the intervention. The intervention dose has been verified in previous work to be safe for participants (Brunfeldt et al., in review). In the event of a participant‚Äôs wish 
to discontinue the protocol before study endpoint, that individual‚Äôs data will be removed from analysis.  
Study #: s23-[ZIP_CODE]    Page 26 of 27 
 
10.4.6 Baseline Descriptive Statistics 
Participants will be selected from the MOBILIS lab registry. We will ensure that both groups (stroke vs. healthy 
control) will have the same number (frequency analysis) of men and women. We will also age match across groups . 
We may perform a t -test on age to ensure parity between groups.  
10.4.7 Planned Interim Analysis 
N/A. Single session study  
[IP_ADDRESS]  Safety Review  
Participants are free to withdraw from participation in the study at any time upon request. An investigator may 
terminate participation in the study if:  
‚Ä¢ Any clinical adverse event (AE) or other medical condition or situation occurs such that continued 
participation in the study would not be in the best interest of the participant  
‚Ä¢ The participant meets an exclusion criterion (either newly developed or not previously recognized) that 
precludes further study participation  
‚Ä¢ The participant fails to adhere to protocol requirements 
‚Ä¢ Subject withdraws consent  
‚Ä¢ Subject experiences excessive fatigue or discomfort  
 Abrupt withdrawal or termination from study will not affect participant safety or clinical management.  
10.5 Sample Size 
Study Hypotheses: (Primary study objective)  
‚Ä¢ A power analysis using a moderate effect size (Cohen‚Äôs f = 0.25 ‚Äì 0.3) on MC, power of 0.8, and significance 
level of 0.05 suggests a total sample of 20- 28 participants (10 -14 per group). This is consistent with previous 
work using shared cursor tasks in stroke (Brunfeldt et al., 2022; Ranganathan et al., 2019) . 
Study Hypotheses: (Secondary study objective)  
‚Ä¢ An a priori  power analysis with an effect size f2 = 0.7 -0.9, a power of 1- Œ≤ = 0.8 and error probability Œ± = 0.[ADDRESS_1153237] size was directly calculated from 
a Partial R2 = 0.4648 using data from a feasibility study currently in preparation for publication. This R2 
value was taken from the relationship between lesion load and the change in MC from baseline to loading 
conditions.  
Assumptions used in calculations:  
‚Ä¢ Assumed normal distribution, or corrected to normal distribution (e.g., via log- transform)  
‚Ä¢ We plan to enroll 30 participants, with between 6- 8 stroke participants not meeting inclusion/exclusion 
criteria. The final N = 12 endpoint accounts for these dropouts.  
‚Ä¢ Data from withdrawn participants will not be included in the final dataset. Only those who complete all 
procedures will be included in the final analyses.  
10.6 Measures to Minimize Bias 
10.6.1 Enrollment/Randomization/Masking Procedures 
Enrollment  will be initiated by [CONTACT_1704], Alexander Brunfeldt, PhD. [CONTACT_830766] will contact [CONTACT_830758], SendSafe Secure email, or MyChart. Stroke participants will be contact[CONTACT_830759]. Healthy control participants will be recruited on a rolling basis to match 
the age and gender of the stroke group. There is no randomization, blinding, or masking proposed.  
11 Source Documents and Access to Source Data/Documents  
Source data is all information, original records of clinical findings, observations, or other activities in a clinical trial 
necessary for the reconstruction and evaluation of the trial.  Source data are contained in source documents.  
Study #: s23-[ZIP_CODE]    Page 27 of 28 
 
Examples of these original documents,  and data records include: hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory notes, memoranda, subjects‚Äô diaries or evaluation checklists, pharmacy dispensing records, recorded 
data from automated instruments, copi[INVESTIGATOR_10379], microfiches, photographic negatives, microfilm or magnetic media, x- rays, subject files, and records kept at the 
pharmacy, at the laboratories, and at medico -technical departments involved in the clinical trial. It is acceptable to 
use CRFs as source documents. If this is the case, it should be stated in this section what data will be collected on CRFs and what data will be collected from other sources.  
 The study case report form (CRF) is the primary data collection instrument for the study.  All data requested on the 
CRF must be recorded.  All missing data must be explained.  If a space on the CRF is left blank because the 
procedure was not done or the question was not asked, write ‚ÄúN/D‚Äù.  If the item is not applicable to the individual 
case, write ‚ÄúN/A‚Äù.  All entries should be printed legibly in black ink.  If any entry error has been made, to correct such 
an error, draw a single straight line through the incorrect entry and enter the correct data above it.  All such  changes 
must be initialed and dated.  DO NOT ERASE OR WHITE OUT ERRORS.  For clarification of illegible or uncertain 
entries, print the clarification above the item, then initial and date it.  
12 Quality Assurance and Quality Control  
QC procedures will be implemented beginning with the data entry system and data QC checks that will be run on 
the database will be generated. Any missing data or data anomalies will be communicated to the site(s) for 
clarification/resolution.  
 
Following written SOPs, the monitors will verify that the clinical trial is conducted and data are generated, 
documented (recorded), and reported in compliance with the protocol, GCP, and the applicable regulatory requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices  (GMP)).  
13 Ethics/Protection of Human Subjects  
13.[ADDRESS_1153238]  
The investigator will ensure that this study is conducted in full conformity with Regulations for the Protection of 
Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, and/or the ICH E6.  
13.[ADDRESS_1153239]  
The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the IRB for review and approval. Approval of both the protocol and the consent form must be obtained before any 
participant is enrolled. Any amendment to the protocol will require review and approval by [CONTACT_3484]. All changes to the consent form will be IRB approved; a determination will 
be made regarding whether previously consented participants need to be re- consented.  
13.3 Informed Consent Process  
13.3.1 Consent/Assent and Other Informational Documents Provided to Participants 
Consent forms describing in detail the study agent, study procedures, and risks are given to the participant and 
written documentation of informed consent is required prior to starting intervention/administering study product. The 
following consent materials are submitted with this protocol:  
 
13.3.2 Consent Procedures and Documentation 
Informed consent is a process that is initiated prior to the individual‚Äôs agreeing to participate in the study and 
continues throughout the individual‚Äôs study participation. Extensive discussion of risks and possible benefits of 
participation will be provided to the participants and their families. Consent forms will be IRB -approved and the 
participant will be asked to read and review the document. The investigator will explain the research study to the participant and answer any questions that may arise. All participants will receive a verbal explanation in terms suited to their comprehension of the purposes, procedures, and potential risks of the study and of their rights as research 
Study #: s23-[ADDRESS_1153240]‚Äôs research record. The consent process, including the name [CONTACT_21811], will be thoroughly documented in the subject‚Äôs 
research record.  Any alteration to the standard consent process (e.g. use of a translator, consent from a legally 
authorized representative, consent document presented orally, etc.) and the justification for such alteration will likewise be documented.  
13.[ADDRESS_1153241] of 1996 (HIPAA).  Those regulations require a signed subject 
authorization informing the subject of the following:  
‚Ä¢ What protected health information (PHI) will be collected from subjects in this study  
‚Ä¢ Who will have access to that information and why  
‚Ä¢ Who will use or disclose that information  
‚Ä¢ The rights of a research subject to revoke their authorization for use of their PHI.  
 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by [CONTACT_5151], retains the 
ability to use all information collected prior to the revocation of subject authorization.  For subjects that have revoked 
authorization to collect or use PHI, attempts should be made to obtain permission to collect at least vital status (i.e. 
that the subject is alive) at the end of their scheduled study period.  
 Participant confi dentiality is strictly held in trust by [CONTACT_3486], their staff, and the sponsor(s) and 
their agents. This confidentiality is extended to cover testing of the clinical information relating to participants. 
Therefore, the study protocol, documentation, data, and all other information generated will be held in strict 
confidence. No information concerning the study or the data will be released to any unauthorized third party without 
prior written approval of the sponsor.  
 
The study monitor, other authorized representatives of the sponsor, or representatives of the IRB may inspect all 
documents and records required to be maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical study site will permit 
access to such records.  
 
The study participant‚Äôs contact [CONTACT_179138]. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated 
by [CONTACT_46202].  
 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be  stored 
on TrialMaster . This will not include the participant‚Äôs contact [CONTACT_1290]. Rather, individual participants 
and their research data will be identified by a unique study identification number. The study data entry and study management systems used by [CONTACT_830760]. At the 
end of the study, all study databases will be de-identified and archived with the Study Investigator and Principal Investigator.  
 
Data will not be shared with additional investigators or third parties without prior approval from the participant. We 
will conform to any institutional, state, or federal auditors need to access data upon reasonable request.  
Study #: s23-[ZIP_CODE]    Page 29 of 30 
 
13.5 Future Use of Data  
Data collected for this study will be analyzed and stored at NYULMC. After the study is completed, the de -identified, 
archived data will be transmitted to and stored at NYIULMC controlled cloud services (e.g., Google Drive), under 
the supervision of Heidi Schambra, MD, for use by [CONTACT_830761].  
 
During the conduct of the study, an individual participant can choose to withdraw consent to have data stored for 
future research. When the study is completed, access to study data and/or samples will be provided through the NYIULMC controlled cloud services.  
[ADDRESS_1153242] Keepi[INVESTIGATOR_007]  
14.1 Data Collection and Management Responsibilities  
Data are collected from four sources:  
‚Ä¢ Six degree of freedom hand position. The 3- dimensional position and 3- dimensional rotation of both Oculus 
Rift touch controllers. Type: electronic  
‚Ä¢ 6- channel electromyography (EMG). EMG muscle activity of the biceps, triceps, and anterior deltoid 
(bilaterally). Type: electgronic  
‚Ä¢ Demographic and characteristic data such as age, sex, height, weight,  handedness, time since stroke, and 
arm length. Type: paper  
‚Ä¢ Medical records will be used to determine the type (ischemic vs. hemorrhagic) and location (cortical, subcortical, left vs. right) of stroke. Medical records will also be used to access the subjec t‚Äôs acute  DWI 
imaging. Type: electronic  
 Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site PI. The 
investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness  of the data reported.  
 
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data. Black 
ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014]. When making changes or corrections, cross out the original 
entry with a single line, and initial and date the change. DO NOT ERASE, OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
 
Copi[INVESTIGATOR_58625] (eCRF) will be provided for use as source documents and maintained for recording 
data for each participant enrolled in the study. Data reported in the eCRF derived from source documents should 
be consistent with the source documents or the discrepancies should be explained and captured in a progress note 
and maintained in the participant‚Äôs official electronic study record.  
 Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and clinical laboratory data will be entered into TrialMaster. a [ADDRESS_1153243] protection and internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the source documents.  
14.1.1 Data Collection Tools ‚Äì Mobile Health Technology 
Products and Device  
The commercial product(s) made by [CONTACT_665463], LLC (Oculus VR headset) and Biometrics Ltd (EMG system) permit recoding of kinematic and muscular activity information and will be used to collect study data. These devices will 
be used in accord with the Terms of Service and/or the End User License Agreements (EULA) provided by [CONTACT_830762]. These products and devices will only be used to collect study data with IRB approval and if the subject has agreed to all applicable Terms of Service.  
14.2 Study Records Retention 
Study documents  will be retained for the longer of 3 years after close -out, 5 years after final reporting/publication, 
or [ADDRESS_1153244] approval of a marketing application is approved for the drug for the indication for which it is 
being investigated or 2 years after the investigation is discontinued and FDA is notified if no application is to be filed 
Study #: s23-[ZIP_CODE]    Page 30 of 31 
 
or if the application has not been approved for such indication. No records will be destroyed without the written 
consent of the sponsor, if applicable. It is the responsibility of the sponsor to inform the investigator when these 
documents no longer need to be retained.  
14.3 Protocol Deviations 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or Manual of Pr ocedures  (MOP)  
requirements. The noncompliance may be either on the part of the participant, the investigator, or the study site staff. As a result of deviations, corrective actions are to be developed by [CONTACT_3483].  
 
These practices are consistent with ICH E6:  
‚Ä¢ 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
‚Ä¢ 5.1 Quality Assurance and Quality Control, section 5.1.1 
‚Ä¢ 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
 
It is the  responsibility of the site PI/study staff to use continuous vigilance to identify and report deviations within [ADDRESS_1153245] be reported to the local IRB per their guidelines. The site PI/study staff is responsible for 
knowing and adhering to their IRB requirements. Further details about the handling of protocol deviations will be included in the MOP.  
14.4 Publication and Data Sharing Policy 
This study will comply with the NIH Public Access Policy, which ensures that the public has access to the published 
results of NIH funded research. It requires scientists to submit final peer -reviewed journal manuscripts that arise 
from NIH funds to the digital archive PubMed Central upon acceptance for publication.  
 The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a clinical trials 
registration policy as a condition for publication. The ICMJE  defines a clinical trial as any research project that 
prospectively assigns human subjects to intervention or concurrent comparison or control groups to study the 
cause -and-effect relationship between a medical intervention and a health outcome. Medical interventions include 
drugs, surgical procedures, devices, behavioral treatments, process -of-care changes, and the like. Health outcomes 
include any biomedical or health- related measures obtained in patients or participants, including pharmacokinetic 
measur es and adverse events. The ICMJE policy, and the Section [ADDRESS_1153246] of 2007, requires that all clinical trials be registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by [CONTACT_1055]. Other biomedical journals are considering 
adopting similar policies. For interventional clinical trials performed under NIH IC grants and cooperative agreements, it is the grantee‚Äôs responsibility to register the trial in an acceptable registry, so the research results 
may be considered for publication in ICMJE member journals. The ICMJE does not review specific studies to 
determine whether registration is necessary; instead, the committee recommends that researchers who have questi ons about the need to register err on the side of registration or consult the editorial office of the journal in 
which they wish to publish.  
 FDAAA mandates that a "responsible party" (i.e., the sponsor or designated principal investigator) register and 
report results of certain "applicable clinical trials":  
‚Ä¢ Trials of Drugs and Biologics: Controlled, clinical investigations, other than Phase I investigations of a 
product subject to FDA regulation;  
‚Ä¢ Trials of Devices: Controlled trials with health outcomes of a product subject to FDA regulation (other than 
small feasibility studies) and pediatric postmarket surveillance studies.  
‚Ä¢ NIH grantees must take specific steps to ensure compliance with NIH implementation of FDAAA.  
Study #: s23-[ADDRESS_1153247]. Heidi Schambra‚Äôs resource allocation funds.  
15.[ADDRESS_1153248], personal costs to the participant other than the participant‚Äôs time. Study costs will be covered 
by [INVESTIGATOR_124]. Schambra‚Äôs RAP package.  
15.3 Participant  Reimbursements or Payments 
Participants in the stroke group will receive a one-time $50 check following their participation in our study. Healthy 
control participants will receive a one -time $25 check. The reason for this difference in value is the potential for 
increased burden on stroke patients regarding transportation (i.e., some are not medically cleared to operate a motor vehicle) and care due to their impairment.  
 The value of reimbursements is set at a level that should not induce or coerce participation. Disbursement of the checks will be made at the completion of the testing session. If the participant wishes to withdraw from the study 
prematurely, they will still receive the check.  
16 Study Administration  
16.1 Study Leadership 
The study leadership consists of Heidi Schambra, MD (PI) and Alexander Brunfeldt, PhD (Study Investigator). [CONTACT_830767] will oversee all aspects of the protocol and ensure that proper rules, regulations, and procedures are followed. [CONTACT_830766] will conduct all aspects of the protocol, including consenting, data collection and analysis, 
preparation of oral and written communications (posters, manuscripts, etc.). The study leadership will meet 
biweekly.  
[ADDRESS_1153249] with this study (patent ownership, royalties, or financial gain greater than the minimum allowable by [CONTACT_1385], etc.) must have the conflict reviewed by [CONTACT_830763] a Committee- sanctioned conflict management plan that has been reviewed and 
approved by [CONTACT_28833].  All NYULMC investigators will follow the applicable 
conflict of interest policies.   
Study #: s23-[ZIP_CODE]    Page 32 of 33 
 
18 References 
 
Brunfeldt, A. T., Bregman, B. S., & Lum, P. S. ( in review ). Responsiveness to exoskeleton loading during bimanual  
reaching is associated with corticospi[INVESTIGATOR_830732].  
Brunfeldt, A. T., Dromerick, A. W., Bregman, B. S., & Lum, P. S. (2022). A tradeoff between kinematic and dynamic 
control of bimanual reaching in virtual reality. Journal of Neurophysiology . 
https://doi.org/10.1152/jn.[ZIP_CODE].2021  
Cassidy, J. M., Tran, G., Quinlan, E. B., & Cramer, S. C. (2018). Neuroimaging Identifies Patients Most Likely to 
Respond to a Restorative Stroke Therapy. Stroke , 49(2), 433‚Äì 438. 
https://doi.org/10.1161/STROKEAHA.117.0 [ZIP_CODE]  
Chen, T., Casas, R., & Lum, P. S. (2019). An Elbow Exoskeleton for Upper Limb Rehabilitation With Series Elastic 
Actuator and Cable -Driven Differential. IEEE Transactions on Robotics , 35(6), 1464 ‚Äì1474. 
https://doi.org/10.1109/TRO.2019.2930915  
Collins , S. H., Wiggin, M. B., & Sawicki, G. S. (2015). Reducing the energy cost of human walking using an 
unpowered exoskeleton. Nature, 522(7555), Article 7555. https://doi.org/10.1038/nature14288 
Diedrichsen, J. (2007). Optimal task -dependent changes of bimanual feedback control and adaptation. Current 
Biology‚ÄØ: CB, 17(19), 1675 ‚Äì1679.  
Duncan, P. W., Bode, R. K., Min Lai, S., & Perera, S. (2003). Rasch analysis of a new stroke -specific outcome 
scale: The stroke impact scale11No commercial party having a direct financial interest in the results of the 
research supporting this article has or will confer a benefit upon the author(s) or upon any organization with 
which the author(s) is/are associated. Archives of Physical Medicine and Rehabilitation, 84(7), 950‚Äì 963. 
https://doi.org/10.1016/S0003- 9993(03)[ZIP_CODE] -2 
Feng, W., Wang, J., Chhatbar, P. Y., Doughty, C., Landsittel, D., Lioutas, V. -A., Kautz, S. A., & Schlaug, G. (2015). 
Corticospi[INVESTIGATOR_830733]: An imaging biomarker for stroke motor outcomes: CST Lesion Load Predicts 
Stroke Motor Outcomes. Annals of Neurology , 78(6), 860‚Äì 870. https://doi.org/10.1002/ana.[ZIP_CODE]  
Gueye, T., Dedkova, M., Rogalewicz, V., Grunerova- Lippertova, M., & Angerova, Y. (2021). Early post -stroke 
rehabilitation for upper limb motor function using virtual reality and exoskeleton: Equally efficient in older patients. Neurologia i Neurochirurgia Polska, 55(1), 6.  
Keeling, A. B., Pi[INVESTIGATOR_830734], M., Semrau, J. A., Hill, M. D., Scott, S. H., & Dukelow, S. P. (2021). Robot enhanced stroke 
therapy optimi zes rehabilitation (RESTORE): A pi[INVESTIGATOR_799]. Journal of NeuroEngineering and Rehabilitation , 
18(1), 10. https://doi.org/10.1186/s12984-021 -[ZIP_CODE]-8 
Kwakkel, G., Veerbeek, J. M., van Wegen, E. E. H., & Wolf, S. L. (2015). Constraint -induced movement therapy 
after stroke. The Lancet Neurology, 14(2), 224‚Äì 234. 
Lin, D. J., Cloutier, A. M., Erler, K. S., Cassidy, J. M., Snider, S. B., Ranford, J., Parlman, K., Giatsidis, F., Burke, 
J. F., Schwamm, L. H., Finklestein, S. P., Hochberg, L. R., & Cramer, S. C. (2019) . Corticospi[INVESTIGATOR_830735]. Stroke , 
50(12), 3569 ‚Äì3577. https://doi.org/10.1161/STROKEAHA.119.025898  
Mazziotta, J., Toga, A., Evans, A., Fox, P., Lancaster, J., Zilles, K., Woods, R., Paus, T., Simpson, G., Pi[INVESTIGATOR_2531], B., 
Holmes, C., Collins, L., Thompson, P., MacDonald, D., Iacoboni, M., Schormann, T., Amunts, K., Palomero -
Gallagher, N., Geyer, S., ‚Ä¶ Mazoyer, B. (2001). A probabilistic atlas and reference system for the human 
Study #: s23-[ZIP_CODE]    Page 33 of 34 
 
brain: International Consortium for Brain Mappi[INVESTIGATOR_007] (ICBM). Philosophical Transactions of the Royal Society 
of London. Series B: Biological Sciences, 356(1412), 1293‚Äì 1322. https://doi.org/10.1098/rstb.2001.0915  
Oldfield, R. C. (1971). The assessment and analysis of handedness: The Edinburgh inventory. Neuropsychologia, 
9(1), 97 ‚Äì113. 
Plagenhoef, S., Evans, F. G., & Abdelnour, T. (1983). Anatomical Data for Analyzing Human Motion. Research 
Quarterly for Exercise and Sport , 54(2), 169‚Äì 178. https://doi.org/10.1080/02701367.1983.10605290  
Ranganathan, R., Gebara, R., Andary, M., & Sylvain, J. (2019). Chronic stroke survivors show task -dependent 
modulation of motor variability during bimanual coordination. Journal of Neurophysiology, 121(3), 756‚Äì 763. 
https://doi.org/10.1152/jn.[ZIP_CODE].2018  
Sainburg, R. L., & Kalakanis, D. (2000). Differences in Control of Limb Dynamics During Dominant and 
Nondominant Arm Reaching. Journal of Neurophysiology, 83(5), 2661 ‚Äì2675. 
https://doi.org/10.1152/jn.2000.83.5.2661 
Stinear, C. M. (2017). Prediction of motor recovery after stroke: Advances in biomarkers. The Lancet Neurology , 
16(10), 826 ‚Äì836. https://doi.org/10.1016/S1474 -4422(17)[ZIP_CODE] -1 
Taub, E., Uswatte, G., Mark, V. W., & Morris, D. M. (2006). The learned nonuse phenomenon: Implications for 
rehabilitation. EUROPA MEDICOPHYSICA, 42, 15.  
Todorov, E., & Jordan, M. I. (2002). Optimal feedback control as a theory of motor coordination. Nature 
Neuroscience, 5(11), 1226 ‚Äì1235.  
Veale, J. F. (2013). Edinburgh Handedness Inventory ‚Äì Short Fo rm: A revised version based on confirmatory factor 
analysis. Laterality: Asymmetries of Body, Brain and Cognition, 19(2), 164‚Äì177. 
https://doi.org/10.1080/1357650X.2013.[ADDRESS_1153250], C. W., Carson, A. P., 
Chamberlain, A. M., Cheng, S., Delling, F. N., Elkind, M. S. V., Evenson, K. R., Ferguson, J. F., Gupta, D. 
K., Khan, S. S., Kissela, B. M., Knutson, K. L., Lee, C. D., Lewis, T. T., ‚Ä¶ On behalf of the American Heart 
Associ ation Council on Epi[INVESTIGATOR_685930]. (2021). Heart Disease and Stroke Statistics‚Äî2021 Update: A Report From the American 
Heart Association. Circulation , 143(8). https://doi.org/10.1161/CIR.0000000000000950  
Wang, J., Lum, P. S., Shadmehr, R., & Lee, S. W. (2021). Perceived effort affects choice of limb and reaction time 
of movements. Journal of Neurophysiology , 125(1), 63 ‚Äì73. https://doi.org/10.1152/jn.[ZIP_CODE].2020  
Wolf, S. L., Winstein, C. J., Miller, J. P., Taub, E., Uswatte, G., Morris, D., Giuliani, C., Light, K. E., Nichols -Larsen, 
D., & EXCITE Investigators,  for the. (2006). Effect of Constraint- Induced Movement Therapy on Upper 
Extremity Function 3 to 9 Months After Stroke: The EXCITE Rand omized Clinical Trial. JAMA , 296(17), 
2095. https://doi.org/10.1001/jama.296.17.2095  
Zhu, L. L., Lindenberg, R., Alexander, M. P., & Schlaug, G. (2010). Lesion Load of the Corticospi[INVESTIGATOR_830736]. Stroke, 41(5), 910 ‚Äì915. 
https://doi.org/10.1161/STROKEAHA.109.577023  
  
Study #: s23-[ADDRESS_1153251] of attachments are included in the IRB Uploads  
‚Ä¢ Aa-Conset_VR_EXO_Imaging  
‚Ä¢ Ab-VR-EXO_Imaging_recruitment flyer  
‚Ä¢ Ac-VR_EXO_Imaging_Datasheet  
‚Ä¢ Ad-Edinburgh Handedness Inventory - Short Form  
‚Ä¢ Ae-Phone_Script_Verbal_Screening  
 
20 Schedule of Events 
Activity Visit Name  
[Day 1]  
Study team procedures    
Consent  X 
Inclusion/exclusion  X 
Demographic Information  X 
Edinburg h Handedness Inventory ‚Äì Short From  X 
Fugl-Meyer Assessment (stroke only; as needed)  X 
Virtual Reality Task (with EMG and exoskeleton)  X 
Access & download neuroimaging  X 
 